Kohta Saito, MD

Highlights

1
Science translational medicine · 2021
KSKohta Saito AGAlexandre Gouzy CDChristopher David Brown BSBen S Gold CFCarl F. Nathan
PMID: 34818059PMCID: PMC8903021DOIFirst author29 citations
2
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2020
KSKohta Saito HWHenry W Murray
PMID: 32114198DOIFirst author2 citations

3 grants

Co-I
Microbiology of Treatment Shortening in Tuberculosis
National Institute of Allergy and Infectious Diseases · 2026–2031
P01AI181935-01A1
Co-I
Multiomic approaches to treatment-shortening compound development and target identification
Bill & Melinda Gates Foundation · 2024–2027
INV-070003
MPI
Interrogating complex mycobacterial population structures using single-cell RNA sequencing
National Institute of Allergy and Infectious Diseases · 2024–2027
R21AI176355-02

Completed grants (1)

PI
Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States
National Institute of Allergy and Infectious Diseases · 2019–2024· 2 renewals
K08AI139360-01

4 studies

PI
SPIND 182989 Clofazimine
Novartis Pharmaceuticals Corporation · OPEN TO ACCRUAL (as of 2026)
PI
SPIND for 182655 for Clofazimine
Novartis Pharmaceuticals Corporation · OPEN TO ACCRUAL (as of 2026)
PI
SPIND 181560 Clofazimine
Novartis Pharmaceuticals Corporation · OPEN TO ACCRUAL (as of 2026)
PI
Clinical significance and epidemiological analysis of Mycobacterium avium complex subspecies in nontuberculous mycobacteria lung infection
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)

Completed & closed trials (7)

PI
SPIND 173516 Clofazimine
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2025)
PI
SPIND 172715 Clofazimine
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2025)
PI
SPIND Clofazimine 172761
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2025)
PI
SPIND: Multiple Patient Program for LampreneÂ® (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections Clofazimine
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
PI
SPIND: 072807 Amphotericin/MAT2203
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
PI
SPIND 173111 Clofazimine
Novartis Pharmaceuticals Corporation · CLOSED TO ACCRUAL (as of 2024)
PI
Treatment of a single patient with mycobacterium abscessus soft tissue infection using Clofazimine (Lamprene)
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2024)

2026 Excellence in Medical Education Awards
June 26, 2026
More than 30 Weill Cornell Medicine faculty and staff were honored June 25 with Excellence in Medical Education Awards at a ceremony held on campus.